TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS
Brief Summary: The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy.


Options:
A: Arm Label: Secukinumab; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Ustekinumab
B: Arm Label: Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 5mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 10mg BID CP-690,550; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5mg BID CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10mg BID CP-690,550
C: Arm Label: Cohort A: INCB018424 Ruxolitinib 0.5%; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib phosphate cream, Drug: Placebo cream | Arm Label: Cohort B: INCB018424 Ruxolitinib 1.0%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort C: INCB018424 Ruxolitinib 1.5%; Type: EXPERIMENTAL; Interventions: Drug: Placebo cream, Drug: Ruxolitinib phosphate cream | Arm Label: Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene; Type: EXPERIMENTAL; Interventions: Drug: Dovonex® calcipotriene 0.005% | Arm Label: Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate; Type: EXPERIMENTAL; Interventions: Drug: Diprolene® AF betamethasone dipropionate 0.05% cream. | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5% | Intervention Type: DRUG; Name: Dovonex® calcipotriene 0.005%; Assigned to Arm(s): Cohort D: 18424 Ruxolitinib vs Dovonex® calcipotriene | Intervention Type: DRUG; Name: Diprolene® AF betamethasone dipropionate 0.05% cream.; Assigned to Arm(s): Cohort E: 18424 Ruxolitinib vs Diprolene® AF betamethasone diproprionate | Intervention Type: DRUG; Name: Placebo cream; Assigned to Arm(s): Cohort A: INCB018424 Ruxolitinib 0.5%, Cohort B: INCB018424 Ruxolitinib 1.0%, Cohort C: INCB018424 Ruxolitinib 1.5% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort B: INCB018424 Ruxolitinib 1.0% | Intervention Type: DRUG; Name: Ruxolitinib phosphate cream; Assigned to Arm(s): Cohort C: INCB018424 Ruxolitinib 1.5%
D: Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Brief Summary: The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.


Options:
A: Arm Label: Control arm: HBIG & vaccine for infants; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: TDF treatment arm; Type: EXPERIMENTAL; Interventions: Drug: TDF treatment | Intervention Type: DRUG; Name: TDF treatment; Assigned to Arm(s): TDF treatment arm
B: Arm Label: Blinded Phase: B/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF, Drug: ABC/DTG/3TC Placebo | Arm Label: Blinded Phase: ABC/DTG/3TC; Type: ACTIVE_COMPARATOR; Interventions: Drug: ABC/DTG/3TC, Drug: B/F/TAF Placebo | Arm Label: Open-Label Phase; Type: EXPERIMENTAL; Interventions: Drug: B/F/TAF | Intervention Type: DRUG; Name: ABC/DTG/3TC; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC | Intervention Type: DRUG; Name: B/F/TAF; Assigned to Arm(s): Blinded Phase: B/F/TAF, Open-Label Phase | Intervention Type: DRUG; Name: ABC/DTG/3TC Placebo; Assigned to Arm(s): Blinded Phase: B/F/TAF | Intervention Type: DRUG; Name: B/F/TAF Placebo; Assigned to Arm(s): Blinded Phase: ABC/DTG/3TC
C: Arm Label: E/C/F/TAF; Type: EXPERIMENTAL; Interventions: Drug: E/C/F/TAF | Arm Label: Stay on Baseline Treatment Regimen (SBR); Type: ACTIVE_COMPARATOR; Interventions: Drug: E/C/F/TDF, Drug: EFV/FTC/TDF, Drug: RTV, Drug: ATV, Drug: FTC/TDF, Drug: COBI | Intervention Type: DRUG; Name: E/C/F/TAF; Assigned to Arm(s): E/C/F/TAF | Intervention Type: DRUG; Name: E/C/F/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: EFV/FTC/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: RTV; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: ATV; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: FTC/TDF; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR) | Intervention Type: DRUG; Name: COBI; Assigned to Arm(s): Stay on Baseline Treatment Regimen (SBR)
D: Arm Label: Tenofovir disoproxil fumarate; Type: EXPERIMENTAL; Interventions: Drug: tenofovir disoproxil fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: tenofovir disoproxil fumarate; Assigned to Arm(s): Tenofovir disoproxil fumarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1 Methodology Issues in a Tailored Light Treatment for Persons With Dementia
Brief Summary: Tailored light treatment will increase sleep efficiency, reduce depression and reduce agitation scores in those with Alzheimer's disease and related dementia


Options:
A: Arm Label: Bright light therapy; Type: EXPERIMENTAL; Interventions: Device: Bright light therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Bright light therapy; Assigned to Arm(s): Bright light therapy
B: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Tailored Active intervention | Arm Label: Inactive intervention; Type: PLACEBO_COMPARATOR; Interventions: Other: Inactive intervention | Intervention Type: OTHER; Name: Tailored Active intervention; Assigned to Arm(s): Active Intervention | Intervention Type: OTHER; Name: Inactive intervention; Assigned to Arm(s): Inactive intervention
D: Arm Label: Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mirtazapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Mirtazapine; Assigned to Arm(s): Mirtazapine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: A randomized controlled study is performed to address the question of whether the topical application of a novel fibrin sealant, Evicel (Johnson \& Johnson Wound Management, Ethicon, Somerville, NJ) in patient undergoing total knee replacement (TKR) reduce the perioperative blood loss and the need for allogenic blood transfusion compared to a control group. We hypothesize that fibrin sealant decrease the drop in post-operative hemoglobin level after total knee replacement.


Options:
A: Arm Label: Vitagel; Type: EXPERIMENTAL; Interventions: Device: Vitagel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vitagel; Assigned to Arm(s): Vitagel
B: Arm Label: Evicel; Type: EXPERIMENTAL; Interventions: Drug: Evicel | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Evicel; Assigned to Arm(s): Evicel
C: Intervention Type: DRUG; Name: IV Tranexamic acid 10mg/kg pt body weight; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quixil topical sealant; Assigned to Arm(s): N/A
D: Arm Label: Intravenous tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5g intravenous Exacyl | Arm Label: Intra-articular tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: 3.0g intra-articular Exacyl | Intervention Type: DRUG; Name: 1.5g intravenous Exacyl; Assigned to Arm(s): Intravenous tranexamic acid | Intervention Type: DRUG; Name: 3.0g intra-articular Exacyl; Assigned to Arm(s): Intra-articular tranexamic acid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men
Brief Summary: The main purpose of this study is to evaluate if testosterone solution can raise testosterone hormone levels into the normal range, and also improve levels of sexual arousal, interest and drive and/or energy level, in men with low testosterone and decreased sexual arousal, interest and drive and/or decreased energy. The study will last about 16 weeks, followed by an optional 24 week open label treatment phase to investigate the long term safety of testosterone solution.


Options:
A: Arm Label: Placebo Solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Solution | Arm Label: Testosterone Solution; Type: EXPERIMENTAL; Interventions: Drug: Testosterone Solution | Intervention Type: DRUG; Name: Testosterone Solution; Assigned to Arm(s): Testosterone Solution | Intervention Type: DRUG; Name: Placebo Solution; Assigned to Arm(s): Placebo Solution
B: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Drug: Topical testosterone gel 1% (active formulation) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Topical gel (placebo formulation) | Intervention Type: DRUG; Name: Topical testosterone gel 1% (active formulation); Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Topical gel (placebo formulation); Assigned to Arm(s): Placebo
C: Arm Label: Active Testosterone Gel; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate (open label), Drug: Testosterone gel | Arm Label: Placebo Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sildenafil citrate (open label), Other: Placebo gel | Intervention Type: DRUG; Name: Sildenafil citrate (open label); Assigned to Arm(s): Active Testosterone Gel, Placebo Gel | Intervention Type: DRUG; Name: Testosterone gel; Assigned to Arm(s): Active Testosterone Gel | Intervention Type: OTHER; Name: Placebo gel; Assigned to Arm(s): Placebo Gel
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral testosterone undecanoate (Andriol) | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral testosterone undecanoate (Andriol); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea
Brief Summary: The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remedē® systems.


Options:
A: Arm Label: acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: acetazolamide | Arm Label: Placebo tablet; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Arm Label: supplemental oxygen during nights; Type: EXPERIMENTAL; Interventions: Other: Supplemental oxygen | Arm Label: Non-invasive ventilation; Type: EXPERIMENTAL; Interventions: Procedure: Non-invasive ventilation | Arm Label: room air; Type: SHAM_COMPARATOR; Interventions: Other: Room air | Intervention Type: DRUG; Name: acetazolamide; Assigned to Arm(s): acetazolamide | Intervention Type: OTHER; Name: Supplemental oxygen; Assigned to Arm(s): supplemental oxygen during nights | Intervention Type: PROCEDURE; Name: Non-invasive ventilation; Assigned to Arm(s): Non-invasive ventilation | Intervention Type: OTHER; Name: Room air; Assigned to Arm(s): room air | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo tablet
B: Arm Label: Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Europe: AutoSet CS (USA: VPAP Adapt SV) | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Europe: AutoSet CS (USA: VPAP Adapt SV); Assigned to Arm(s): Treatment Group
C: Arm Label: #1 (Acetazolamide-placebo); Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide-placebo | Arm Label: #2 (Placebo-acetazolamide); Type: EXPERIMENTAL; Interventions: Drug: Placebo-acetazolamide | Intervention Type: DRUG; Name: Acetazolamide-placebo; Assigned to Arm(s): #1 (Acetazolamide-placebo) | Intervention Type: DRUG; Name: Placebo-acetazolamide; Assigned to Arm(s): #2 (Placebo-acetazolamide)
D: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Treatment Group (transvenous stimulation of the phrenic nerve) | Arm Label: Control group; Type: OTHER; Interventions: Device: Control Group (Optimal Medical Therapy) | Intervention Type: DEVICE; Name: Treatment Group (transvenous stimulation of the phrenic nerve); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: Control Group (Optimal Medical Therapy); Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Deconstruction of Human Milk Oligosaccharides and Lipids
Brief Summary: This observational study is designed to determine how sugars, lipids and proteins in breast milk vary among mothers; is affected by maternal diet, health and microbiota and vary over the course of lactation. Additionally, the study is designed to determine how the structure and composition of complex milk sugars, maternal health status and diet influence the development and maintenance of infant gut microflora.


Options:
A: Arm Label: probiotics group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: probiotics | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: glucose solution | Intervention Type: DIETARY_SUPPLEMENT; Name: probiotics; Assigned to Arm(s): probiotics group | Intervention Type: DIETARY_SUPPLEMENT; Name: glucose solution; Assigned to Arm(s): control group
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium bifidum supplementation | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo contains dextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium bifidum supplementation; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo contains dextrin; Assigned to Arm(s): Placebo
C: Arm Label: Main Study; Type: N/A; Interventions: N/A | Arm Label: Gestational Diabetes Mellitus Cohort; Type: N/A; Interventions: N/A | Arm Label: Fresh Milk Cohort; Type: N/A; Interventions: N/A | Arm Label: RNA Milk Fat Cohort; Type: N/A; Interventions: N/A | Arm Label: Skin Study; Type: N/A; Interventions: N/A | Arm Label: BMMI Project; Type: N/A; Interventions: N/A
D: Arm Label: Bifidobacterium lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin, Dietary Supplement: İnulin | Arm Label: İnulin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Other: Maltodextrin | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Dietary Supplement: Bifidobacterium lactis plus İnülin, Dietary Supplement: İnulin | Arm Label: Bifidobacterium lactis plus İnülin; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium lactis, Other: Maltodextrin, Dietary Supplement: İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis; Assigned to Arm(s): Bifidobacterium lactis plus İnülin, Maltodextrin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium lactis plus İnülin; Assigned to Arm(s): Bifidobacterium lactis, Maltodextrin, İnulin | Intervention Type: OTHER; Name: Maltodextrin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, İnulin | Intervention Type: DIETARY_SUPPLEMENT; Name: İnulin; Assigned to Arm(s): Bifidobacterium lactis, Bifidobacterium lactis plus İnülin, Maltodextrin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study
Brief Summary: The purpose of this study is to determine whether infliximab can favourably and safely be discontinued in patients with Crohn's disease in sustained complete clinical, biochemical, and endoscopic remission on infliximab.

Further to examine the clinical utility of measuring levels/activity of infliximab and activity of anti-infliximab Ab in patients in sustained complete remission, in order to investigate whether pharmacoimmunological data can predict the clinical outcome and rationalize therapeutic management of these patients with respect to continuation or discontinuation of infliximab therapy. Additional, to investigate the optimal time-point, out of three, to measure this activity.


Options:
A: Arm Label: INFLIXIMAB AND ANTI METABOLITE; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: STOP INFLIXIMAB CONTINUING ANTI METABOLITE; Type: OTHER; Interventions: Drug: INFLIXIMAB | Arm Label: CONTINUING INFLIXIMAB AND discontinuing anti-metabolites; Type: OTHER; Interventions: Drug: AZATHIOPRINE, Drug: MERCAPTOPURINE, Drug: Methotrexate | Intervention Type: DRUG; Name: INFLIXIMAB; Assigned to Arm(s): STOP INFLIXIMAB CONTINUING ANTI METABOLITE | Intervention Type: DRUG; Name: AZATHIOPRINE; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites | Intervention Type: DRUG; Name: MERCAPTOPURINE; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): CONTINUING INFLIXIMAB AND discontinuing anti-metabolites
B: Arm Label: infliximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): infliximab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Usual Care practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Algorithm; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment Algorithm for Crohn's Disease | Intervention Type: OTHER; Name: Treatment Algorithm for Crohn's Disease; Assigned to Arm(s): Treatment Algorithm
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Measurement of serum infliximab and anti-infliximab antibodies | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status | Intervention Type: PROCEDURE; Name: Measurement of serum infliximab and anti-infliximab antibodies; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial.
Brief Summary: After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days. Patients who are found to be unresponsive as per Lille's score \[\>0.45\] would be randomized into either placebo group or G-CSF group. Responders to steroids will continue on steroids for 28 days followed by 2 weeks of tapering. Non responders will be randomized to receive G-CSF for 28days.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: G-CSF | Arm Label: G-CSF; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): G-CSF
B: Arm Label: G-CSF + Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: G-CSF, Other: Standard therapy | Arm Label: Standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): G-CSF + Standard therapy, Standard therapy
C: Arm Label: G-CSF+EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+EPO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF+EPO; Assigned to Arm(s): G-CSF+EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Standard Medical Therapy + G CSF Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF | Arm Label: Standard Medical Therapy + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): Standard Medical Therapy + G CSF Therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard Medical Therapy + Placebo

Answer: A